Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shared neoantigen peptide vaccine
- Development stage
- Unknown
- Lead developer
- Nanjing Drum-Tower Hospital
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
A shared neoantigen peptide vaccine developed for the treatment of non-small cell lung cancer (NSCLC). The vaccine is based on a library of 44 high-affinity peptides derived from common hotspot mutations in key NSCLC genes, including EGFR, TP53, KRAS, CTNNB1, CDKN2A, and HER-2. It is designed to stimulate neoantigen-specific T-cell activation and induce cytotoxic T-lymphocyte (CTL) responses against tumor cells. In clinical studies, it has been evaluated in combination with chemotherapy and PD-1 blockade for patients with advanced, TKI-resistant NSCLC, showing promising efficacy and a manageable safety profile.
- Other names
- shared neoantigen peptide libraryshared neoantigen vaccine
02
Targets
γδ TCR (T-cell receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TP53 (Cellular tumor antigen p53)CTNNB1 (Beta-catenin)CDKN2A (Cyclin-dependent kinase inhibitor 2A)Mutant peptide-human leukocyte antigen complexes
Beyond the preview
Go deeper on shared neoantigen peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shared neoantigen peptide vaccine.